Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Chan

Showing results (21-30 of 271) with videos related to

Pageof 28
Sort By:
Cancer Cell|May 16, 2019
Lung Cancer Evolution: What's Immunity Got to Do with It?Luc G T Morris, Timothy A Chan
The Journal of Clinical Investigation|June 15, 2022
Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacyAhmed Halima, Winston Vuong, Timothy A Chan
Oncotarget|January 18, 2012
Resistance to EGFR inhibitors: molecular determinants and the enigma of head and neck cancerLuc G T Morris, Timothy A Chan
Nature Reviews. Clinical Oncology|June 16, 2023
Antigen presentation in cancer - mechanisms and clinical implications for immunotherapyKailin Yang, Ahmed Halima, Timothy A Chan
The New England Journal of Medicine|November 13, 2015
Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaTimothy A Chan, Jedd D Wolchok, Alexandra Snyder
Oncotargets and Therapy|April 10, 2013
Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer managementAllen S Ho, Sevin Turcan, Timothy A Chan
Nature Reviews. Cancer|February 14, 2019
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapyJonathan J Havel, Diego Chowell, Timothy A Chan
The New England Journal of Medicine|February 19, 2015
Genetic basis for clinical response to CTLA-4 blockadeAlexandra Snyder, Jedd D Wolchok, Timothy A Chan
JAMA Oncology|June 10, 2021
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker-ReplyCristina Valero, Timothy A Chan, Luc G T Morris
Protein & Cell|March 14, 2014
Driver mutations of cancer epigenomesDavid M Roy, Logan A Walsh, Timothy A Chan
Pageof 28

Showing results (21-30 of 271) with videos related to

Sort By:
Pageof 28
Cancer Cell|May 16, 2019
Lung Cancer Evolution: What's Immunity Got to Do with It?Luc G T Morris, Timothy A Chan
The Journal of Clinical Investigation|June 15, 2022
Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacyAhmed Halima, Winston Vuong, Timothy A Chan
Oncotarget|January 18, 2012
Resistance to EGFR inhibitors: molecular determinants and the enigma of head and neck cancerLuc G T Morris, Timothy A Chan
Nature Reviews. Clinical Oncology|June 16, 2023
Antigen presentation in cancer - mechanisms and clinical implications for immunotherapyKailin Yang, Ahmed Halima, Timothy A Chan
The New England Journal of Medicine|November 13, 2015
Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaTimothy A Chan, Jedd D Wolchok, Alexandra Snyder
Oncotargets and Therapy|April 10, 2013
Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer managementAllen S Ho, Sevin Turcan, Timothy A Chan
Nature Reviews. Cancer|February 14, 2019
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapyJonathan J Havel, Diego Chowell, Timothy A Chan
The New England Journal of Medicine|February 19, 2015
Genetic basis for clinical response to CTLA-4 blockadeAlexandra Snyder, Jedd D Wolchok, Timothy A Chan
JAMA Oncology|June 10, 2021
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker-ReplyCristina Valero, Timothy A Chan, Luc G T Morris
Protein & Cell|March 14, 2014
Driver mutations of cancer epigenomesDavid M Roy, Logan A Walsh, Timothy A Chan
Pageof 28